The psychedelic psilocybin might have a role in the treatment of anorexia (AN), an eating condition that is infamously challenging and costly to deal with.
In a really small stage 1 trial of 10 women with AN, a single 25-mg dosage of psilocybin coupled with mental support, was safe and well-tolerated and reduced eating-disorder habits in some of the individuals.
Stephanie Knatz Peck, PhD, and associates with the Eating Disorders Treatment & Research Center, University of California San Diego, write that the “robust action” in a subset of ladies after a single dose of psilocybin is “significant,” given that presently offered treatments for adult anorexia result in only modest enhancements in signs and typically concentrate on weight and dietary rehabilitation without effectively resolving underlying psychopathology.
Nevertheless, offered this was a small, phase 1, open-label expediency research study, these effects are “preliminary and undetermined,” they warn.
The study was released online July 24 in Nature Medication.
Significant Experience
The 10 ladies in the research study met DSM-5 criteria for AN or partial remission of AN. They were in between age 18 and 40 years with a mean BMI of 19.7 kg/m2.
Following the single 25-mg dose of psilocybin, no medically considerable changes were observed in ECG, essential signs, laboratory values, or suicidality.
All unfavorable events were moderate and mirrored normal psilocybin-associated signs such as transient headache, queasiness, and fatigue.
Psilocybin was connected with lowered levels of stress and anxiety and fixations surrounding food, eating, and body shape at the 1-month follow-up.
Weight concerns reduced substantially at the 1-month (P =.036, Cohen’s d =.78) and 3-month (P = .04, d =.78) follow-up, with a medium to large effect.
Shape concerns considerably reduced at 1-month follow-up (P =.036, d =.78) however were no longer considerable at 3-month follow-up (P =.081, d =.62).
Four of the 10 females (40%) had scientifically significant reductions in consuming condition ratings at 3 months, which qualified for remission from eating-disorder psychopathology.
However, the researchers warn, that the effects on eating condition psychopathology were “extremely variable.”
Typically, modifications in BMI were not considerable throughout the 3 months following psilocybin treatment. However, 5 ladies had a boost in BMI at 3 months, varying from 0.4 to 1.2 kg/m2.
Overall, the psilocybin experience was considered significant by individuals; 80% endorsed the experience as one of the top 5 most meaningful of life; 90% backed feeling more positive about life endeavors; and 70% reported experiencing a shift in personal identity and general quality of life.
The huge majority of females (90%) felt that one dosing session was inadequate.
The truth that the treatment was considered beneficial by the majority of women and that there were no dropouts are “appealing indications of engagement,” given that dropout rates for presently readily available AN treatments tend to be high, the researchers note.
They advise caution in interpreting the results considering they were based upon a little sample size and did not include a placebo group. They note that bigger, properly powered, randomized controlled trials are needed to draw any conclusions about the function of psilocybin for anorexia.
Encouraging Data
The co-authors of a Nature Medicine News & Views commentary state this “encouraging” phase 1 trial “underscores the necessity for more research into timeless psychedelics to address the immediate requirement for effective treatments” for AN.
Outside professionals also weighed in on the study in a statement from the UK-based nonprofit Science Media Centre.
Alexandra Pike, DPhil, MSc, with University of York, UK, noted that this research study is “a primary step in revealing that psilocybin might be a safe treatment for those with anorexia nervosa, however we can not conclude from this work that it will work in this persistent, complex health problem.”
Also weighing in, Trevor Steward, MD, with University of Melbourne, Australia, kept in mind that psilocybin treatment has actually provided “twinkles of hope in other psychological health disorders, notably by supplying proof that it can improve anxiety, cognitive flexibility, and self-acceptance for some people. These are all features of anorexia and the rationale for exploring psilocybin therapy as an alternative when it comes to anorexia is strong.”
Steward also noted that the field is just beginning to “scratch the surface in terms of comprehending how psilocybin affects the brain. Dedicated financing to checking out how it specifically acts to target anorexia signs is important to advancing this essential avenue of research.
“As there are no approved medications available particularly for anorexia treatment, psilocybin treatment may show to be an appealing option, though additional research study is required to evaluate this,” Steward stated.
The study used an investigational artificial formula of psilocybin (COMP360 psilocybin) developed by COMPASS Pathways, which moneyed the study. T wo authors have financial and scientific relationships with COMPASS Pathways. The News & Views authors and Steward report no relevant financial relationships. Disclosures for Pike were unavailable at press time.
Nature Medication. Published online July 24, 2023. Complete text, Editorial
For more Medscape Psychiatry news, join us on Twitter and Facebook
In a phase 1 study, a single dose of psilocybin with psychological assistance was safe and well-tolerated, and it reduced eating-disorder behaviors in some ladies with anorexia nervosa.
